GFAP Antibody / Glial Fibrillary Acidic Protein Antibody

GFAP Antibody Overview

GFAP Antibody reagents target glial fibrillary acidic protein (GFAP), the primary intermediate filament protein of astrocytes. GFAP provides cytoskeletal support, stabilizes cellular extensions, and participates in interactions with neurons and blood vessels. Astrocytes expressing GFAP play crucial roles in regulating neurotransmission, forming the blood–brain barrier, and responding to CNS damage.

GFAP is a hallmark marker of astrocytic lineage and reactive gliosis. Its expression is elevated following trauma, stroke, and neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease. Mutations in GFAP are also linked to Alexander disease, a rare leukodystrophy caused by astrocytic dysfunction. The GFAP Antibody is therefore a cornerstone reagent for studying astrocyte biology, neuroinflammation, and CNS disease, while the Glial Fibrillary Acidic Protein Antibody supports broad applications in both basic and translational neuroscience.

Why Choose GFAP Antibodies from NSJ Bioreagents?

NSJ Bioreagents offers GFAP Antibodies validated for immunohistochemistry, immunofluorescence, western blotting, ELISA, and flow cytometry. Each GFAP Antibody is tested rigorously to ensure sensitivity and specificity, minimizing cross-reactivity with non-astrocytic proteins.

By selecting a GFAP Antibody from NSJ Bioreagents, researchers gain confidence in reproducibility. Our antibodies provide bright, specific astrocyte staining in tissue sections, consistent detection in protein lysates, and robust results across platforms. Detailed datasheets, recommended controls, and optimized protocols further enhance reproducibility and clarity.

Applications of GFAP Antibodies

The GFAP Antibody supports diverse research and clinical applications in neuroscience, pathology, and translational medicine.

1) Astrocyte Identification and Biology

• GFAP Antibodies define astrocytic populations in brain and spinal cord.

• The GFAP Antibody supports mapping of astrocyte networks in neural circuits.

• Glial Fibrillary Acidic Protein Antibody products help clarify astrocyte differentiation.

2) CNS Injury and Reactive Gliosis

• GFAP Antibodies detect astrocyte activation following trauma, ischemia, or hypoxia.

• The GFAP Antibody highlights scar formation after spinal cord injury.

• Glial Fibrillary Acidic Protein Antibody reagents monitor glial response in neurorepair models.

3) Neurodegenerative Disease

• GFAP Antibodies are applied in Alzheimer’s, ALS, Huntington’s, and Parkinson’s studies.

• The GFAP Antibody tracks astrocytic changes during disease progression.

• Glial Fibrillary Acidic Protein Antibody reagents support biomarker development for early detection.

4) Neuroinflammation and Autoimmune Disorders

• GFAP Antibodies highlight astrocyte involvement in multiple sclerosis.

• The GFAP Antibody supports research into neuroimmune signaling pathways.

5) Oncology and Glioma Research

• GFAP Antibodies are diagnostic markers for astrocytomas and glioblastomas.

• The GFAP Antibody helps distinguish astrocytic tumors from oligodendroglial or metastatic cancers.

• Glial Fibrillary Acidic Protein Antibody tools provide prognostic biomarkers in neuro-oncology.

6) Developmental Neuroscience

• GFAP Antibodies clarify astrocyte lineage commitment during embryonic brain development.

• The GFAP Antibody supports studies of radial glia, progenitors that guide neurogenesis.

7) Translational Medicine and Clinical Studies

• GFAP Antibodies validate biomarkers in serum and cerebrospinal fluid.

• The GFAP Antibody supports clinical trials in traumatic brain injury and stroke therapies.

• Glial Fibrillary Acidic Protein Antibody reagents help develop non-invasive diagnostic assays.

Why Are GFAP Antibodies Important?

Astrocytes are essential regulators of CNS function and pathology, and the GFAP Antibody provides a precise means of detecting them. The Glial Fibrillary Acidic Protein Antibody complements these tools by supporting diverse applications in neuroscience, oncology, and translational medicine.

In basic research, GFAP Antibodies map astrocyte networks and clarify glial roles in synaptic support. In injury and repair studies, the GFAP Antibody reveals scar formation and regenerative potential. In disease-focused research, Glial Fibrillary Acidic Protein Antibody reagents highlight astrocyte activation in neurodegeneration and gliomas.

Clinically, GFAP detection is moving beyond pathology into biomarker testing. Elevated GFAP levels in serum or cerebrospinal fluid are being investigated as indicators of traumatic brain injury, multiple sclerosis activity, and neurodegeneration. The GFAP Antibody therefore links bench science to clinical translation, ensuring reliable insights into astrocytic health and disease.

Conclusion

GFAP is the definitive astrocytic marker, widely applied across basic neuroscience, pathology, and translational research. The GFAP Antibody equips researchers and clinicians with a reliable reagent for detecting glial fibrillary acidic protein, while the Glial Fibrillary Acidic Protein Antibody provides broader support across disease research and biomarker validation. By ensuring specificity and reproducibility, these antibodies remain indispensable tools for advancing neuroscience and improving clinical outcomes.